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Abstract: Mutations in the LMNA gene, encoding the nuclear envelope A-type lamins, are 
responsible for muscular dystrophies, the most severe form being the LMNA-related congenital 
muscular dystrophy (L-CMD), with severe defects in myonucleus integrity. We previously reported 
that L-CMD mutations compromise the ability of muscle stem cells to modulate the yes-associated 
protein (YAP), a pivotal factor in mechanotransduction and myogenesis. Here, we investigated the 
intrinsic mechanisms by which lamins influence YAP subcellular distribution, by analyzing 
different conditions affecting the balance between nuclear import and export of YAP. In contrast to 
wild type (WT) cells, LMNADK32 mutations failed to exclude YAP from the nucleus and to inactivate 
its transcriptional activity at high cell density, despite activation of the Hippo pathway. Inhibiting 
nuclear pore import abolished YAP nuclear accumulation in confluent mutant cells, thus showing 
persistent nuclear import of YAP at cell confluence. YAP deregulation was also present in congenital 
myopathy related to nesprin-1 KASH mutation, but not in cells expressing the LMNAH222P mutation, 
the adult form of lamin-related muscle dystrophy with reduced nuclear deformability. In 
conclusion, our data showed that L-CMD mutations increased YAP nuclear localization via an 
increased nuclear import and implicated YAP as a pathogenic contributor in muscle dystrophies 
caused by nuclear envelop defects. 
Keywords: lamins; congenital myopathy; nucleo-cytoskeletal translocation; nuclear envelope 
 
1. Introduction 
The nuclear lamins A/C are type V intermediate filament proteins encoded by the LMNA gene. 
Lamins form complexes with other proteins of the nuclear membrane to influence mechanical cues 
and signaling pathways crucial for cellular proliferation and differentiation [1]. Mutations in the 
LMNA gene cause laminopathies, a highly heterogeneous group of disorders, including muscular 
dystrophies and cardiomyopathies [2,3]. The disease mechanisms underlying LMNA-related 
muscular dystrophy remains somewhat elusive. 
There is clear evidence that A-type lamins and nuclear envelope proteins play a critical role in 
responding to mechanical cues from the extracellular matrix by adjusting the cytoskeleton and 
nuclear stiffness with the stiffness of the tissue microenvironments [4,5]. Structural changes in lamin 
A/C can also affect several signaling pathways, by altering either direct or indirect interactions of 
signaling molecules with A-type lamins [6,7]. Lamins A/C have already been shown to regulate the 
nuclear translocation and downstream signaling of the mechanosensitive transcription factor 
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megakaryoblastic leukemia 1 (MKL1), a myocardin family member pivotal in cardiac development 
and function [8]. In muscle stem cells (MuSCs) from patients carrying A-type lamin mutations, we 
recently reported an impaired ability to sense matrix stiffness [9] and to withstand mechanical 
stretching of the extracellular matrix, causing aberrant regulation of the yes-associated protein (YAP) 
[10]. 
YAP is a transcriptional co-regulator that is modulated by diverse biomechanical signals and 
transduces them into cell-specific transcriptional responses, regulating cell proliferation and survival, 
organ growth, stem-cell renewal, and cell differentiation [11]. A major mechanism of YAP regulation 
occurs at the level of its subcellular localization, as YAP nuclear accumulation promotes target gene 
transcription and cell proliferation (reviewed in [11,12]). After phosphorylation by LATS1/2 kinase, 
YAP binds to 14–3–3 proteins, leading to its cytoplasmic retention and degradation (reviewed in 
[11,12]), and favoring skeletal muscle differentiation [12]. 
A-type lamins influence the localization and transcriptional activity of YAP [10]. It has been 
shown that lamin-A overexpression decreases both total YAP levels and nuclear localization in 
mesenchymal stem cells [5]. In contrast, increased YAP nuclear localization and activity in 
combination with reduced lamin levels is observed in cancers of many organ types (reviewed in [13]), 
as well as in LMNA mutant MuSCs cultured on soft matrices [10]. However, it remains unclear as to 
how mutant lamins cause defects in the YAP signaling pathway. Abnormal nuclear shape is observed 
in diseases where the A-type lamins are altered, including cancer [14,15] and laminopathies [16]. 
Altered nuclear morphology can in turn increase the rate of YAP import [17,18], by opening up 
nuclear pores [17]. One can hypothesize that A-type lamin mutations, responsible for severe skeletal 
muscle laminopathies, will cause an increase YAP nuclear localization because of an increased 
nuclear import. 
To test this hypothesis, we investigated YAP subcellular distribution/activity in MuSCs with A-
type lamin mutations responsible for severe congenital muscle dystrophy (L-CMD) in different 
conditions affecting the balance between nuclear import and export of YAP. Our study provides 
evidence that A-type lamin mutations impair YAP regulation by increasing the nuclear import of 
YAP. Intriguingly, we also found YAP nuclear accumulation in cells with nesprin-1 mutation 
responsible for a congenital myopathy and associated with defects in nuclear morphology [9,19], but 
not in cells carrying the LMNAH222P mutation responsible for a less severe form of the disease and 
much milder nuclear envelope structural defects. These findings support a causative role of nuclear 
envelope defects in abnormal YAP signaling and implicated YAP as a pathogenic contributor in the 
severity of muscle dystrophies caused by nuclear envelop mutations. Overall, our study gains insight 
into broader questions of how lamins and nuclear shape impact cellular function. 
2. Materials and Methods 
2.1. Human Cells and Cell Culture 
We obtained muscle biopsies from the Bank of Tissues for Research (Myobank, a partner in the 
EU network EuroBioBank) in accordance with European recommendations and French legislation. 
All patients provided written informed consent and experimental protocols were approved by our 
institution (INSERM) (approval number AC-2013-1868, 28 May 2014 and AC-2019-3502, 2 Dec 2019). 
Experiments were performed using immortalized L-CMD human myoblasts carrying a heterozygous 
LMNAc.94_96delAAG, p.Lys32del (referred to as K32), LMNA p.Arg249Trp (referred to as R249W), 
or LMNA p.Leu380Ser (referred to as L380S) mutation. Immortalized human myoblasts carrying 
SYNE-1 homozygous c.23560 G<T, p.E7854X leading to a stop codon in exon 133 and deletion of the 
carboxy-terminal KASH domain (referred to as nesprin-1KASK) were also analyzed, given that this 
mutation alters the nuclear shape of MuScs [9,20]. Immortalized myoblasts, obtained from two 
healthy control subjects without muscular disorders, were used as controls (hereafter referred to 
wild-type, WT). 
We also analyzed myogenic cells derived from fibroblasts obtained from a patient with classical 
form of EDMD and carrying the LMNA p.H222P mutation (LMNAH222P), and from a control patient 
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[21]. Fibroblasts were obtained from skin biopsies and immortalized as previously described [22]. 
Doxycycline-inducible Myod1 lentivirus was used to induce myogenic conversion [23]. 
Following muscular biopsy, MuSCs were immortalized and cultured in growth medium 
consisting of 1 vol 199 Medium /4 vol DMEM (Life Technologies, Carlsbad, CA, USA) supplemented 
with 20% fetal calf serum (Life Technologies), 5 ng/mL hEGF (Life Technologies), 0.5 ng/mL FGF, 
0.1 mg/mL Dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), 50 µg/mL fetuin (Life 
Technologies), 5 µg/mL insulin (Life Technologies), and 50 mg/mL Gentamycin (GibcoTM, Life 
Technologies, Carlsbad, CA, USA). MyoD-transfected fibroblasts were cultured in a proliferation 
medium consisting of DMEM, supplemented with 10% fetal bovine serum (Life Technologies) and 
0.1% gentamycin (Invitrogen, Carlsbad, CA, USA). 
All cells were cultured on classic glass or plastic substrates. In addition, micro patterned glass 
slides with round islands of 700 µm2 (4D Cell, Montreuil, France) were coated with fibronectin and 
cells were seeded in a 200 µL drop at the center of the dish. After attachment, the wells containing 
the micro patterned slides were filled with proliferative medium for 24 h. 
2.2. Drug Treatments 
Importazole, a drug that blocks importin--dependent nuclear import [24], Leptomycin B, a drug 
that blocks CRM1-dependent nuclear export [25] or Dasatinib, Src-family kinase inhibitor drugs were 
diluted to final concentration of 40 µM, 100 nM, or 100 nM, respectively, for 24, 24, or 1 h. Latrunculin-
A (Lat A, Sigma-Aldrich) or Cytochalasin D (Sigma-Aldrich) were diluted to final concentration of 
2.0 and 1 µM, respectively, for 20 or 30 min. Vehicle control experiments using appropriate doses and 
time of dimethylsulfoxyde (DMSO) were used to assess the effects of specific drugs. 
2.3. Luciferase Reporter Assays 
MuSCs were transfected with Lipofectamine® 2000 (Invitrogen) reagents in growth media 
without antibiotics according to manufacturer’s instructions. TBS (Tead binding sequence: 14 times 
GGAATG)-Firefly Luciferase reporter constructs were used at a 1:5 ratio to the co-reporter vector for 
the weak constitutive expression of wild-type Renilla luciferase (pRL-TK, Promega GmbH, 
Mannhein, Germany). Transfected cells were seeded onto 24-, 48-, or 96-well plates and recovered 
overnight in growth medium. For the luciferase assay, cells were cultivated for 24 h after transfection 
under the stated conditions. The cells were lysed with passive lysis buffer (PJK GmbH, 
Kleinblittersdorf, Germany) and activity of the reporter was quantified by addition of firefly 
Luciferase substrate Beetle Juice (PJK GmbH). The activity of Renilla luciferase was quantified by 
addition of Renilla Juice (PJK GmbH) and measuring luciferase activity with Mithras LB940 
Luminometer (Wildbad, Germany). Three separate experiments were performed per condition. 
2.4. Immunocytochemistry and Image Analysis 
MuSCs were fixed for 5 min with 4% formaldehyde, permeabilized with 0.1%Triton X100, and 
blocked with 10% bovine serum albumin (BSA) diluted in PBS. Cells were stained with Phalloidin-
Alexa 568 to label F-actin (Interchim, Montluçon, France). The following primary antibodies were 
used for immunostaining: anti- Yes-associated protein (YAP)/ transcriptional coactivator with PDZ-
binding motif (TAZ) (Santa-Cruz, Dallas, TX, USA, sc-10119s), anti-phosphorylated Ser127 YAP 
(pS127-YAP) (Cell Signaling, Danvers, MA, USA, cs-4911), and anti-phosphorylated Tyr357-YAP (pY357-
YAP) (Abcam, Paris, France, ab62751). Secondary antibodies (Life Technologies, Saint-Aubin, France; 
1/500) were Alexa Fluor 488 donkey anti-mouse IgG or Alexa Fluor 488 donkey anti-rabbit IgG. 
Nuclei were stained with Hoechst (ThermoFischer, Carlsbad, CA, USA) and Mowiol was used as 
mounting medium. Confocal images were taken with an Olympus FV 1200 (Olympus, Hamilton, 
Bermuda) and a laser-scanning microscopy Nikon Ti2 coupled to a Yokogawa CSU-W1 head (Nikon, 
Tokyo, Japan). 
All image analyses were performed using Fiji software (NIH Image, version 1.51). For 
immunostained cells, Z-stacks of images were acquired for each channel, and the middle confocal 
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slice was chosen from the images of the nucleus detected in the Hoechst channel. On the 
corresponding slice in the YAP channel, the average fluorescence intensity in the nucleus and just 
outside the nucleus (cytoplasm) was measured to determine the nuclear/cytoplasmic ratio.  
2.5. SDS-PAGE and Protein Analysis 
Cells were lysed in total protein extraction buffer (50 mM Tris-HCl, pH 7.5, 2% SDS, 250 mM 
sucrose, 75 mM urea, 1 mM DTT) with added protease inhibitors (25 µg/mL Aprotinin, 10 µg/mL 
Leupeptin, 1 mM 4-[2-aminoethyl]-benzene sulfonylfluoride hydrochloride, and 2 mM Na3VO4) or 
directly in 2× Laemmli buffer. Protein lysates were separated by SDS-PAGE and transferred on PVDF 
or nitrocellulose membranes. After blocking with bovine serum albumin, membranes were incubated 
with anti-YAP (Santa-Cruz, CA, USA, sc-10119), anti-pS127-YAP (Cell Signaling, Danvers, MA, USA, 
cs-4911), and anti-pY357-YAP (Abcam, Paris, France, ab62751) or anti-GAPDH (Cell Signaling, cs-2118). 
Goat anti-mouse, goat anti-rat, or donkey anti-goat HRP conjugates were used for HRP-based 
detection. Detection of adsorbed HRP-coupled secondary antibodies was performed by ECL reaction 
with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA). HRP 
signals were detected using a CCD-based detection system (Vilber Lourmat, Marne-La-Vallée, 
France) or a G-box system with GeneSnap software (Ozyme, Saint-Quentin, France). Membranes 
subjected to a second round of immunoblotting were stripped with stripping buffer (62.5 mM Tris-
HCL pH 6.8, 2% sodium dodecyl sulfate (SDS), 100 mM β-mercaptoethanol) and incubated at 55 °C 
for 30 min with mild shaking before excessive washing with deionized water and re-blocking. 
Quantification was performed using ImageJ (NIH Image). 
2.6. Quantification of Gene Expression 
The mRNA was isolated from cell lysates using the RNeasy mini kit (Qiagen, Hilden, Germany) 
with the Proteinase K step, according to the manufacturer instructions. The complementary DNA 
(cDNA) was transcribed by SuperscriptIII (ThermoFischer, Carlsbad, CA, USA). Gene expression was 
quantified by using PerfeCTa-SYBR®Green SuperMix (Quanta, Biosciences, Gaithersburg, USA) 
with the help of LightCycler 480 II (Roche Diagnostics GmbH, Mannheim, Germany). The primers 
were designed by Primer-BLAST (NCBI) and synthesized by Eurogentec (Liège, Belgium). 
Expression of all target genes was normalized to the expression of the reference gene RPLP0. Primer 
sequences are listed in Table 1. 
2.7. Statistical Analysis 
Graphpad Prism (Graphpad Software, La Jolla, California) was used to calculate and plot mean 
and standard error of the mean (SEM). Statistical significances were assessed by ANOVA followed 
by Bonferroni or two-tailed unpaired t-tests. Differences between conditions were considered 
significant at p < 0.05. Figures were plotted with Graphpad Prism. 
Table 1. Primer sequences. 
Gene name Abbreviation Forward/Reverse Sequence 
Human  
Yes-associated protein 1 
hYAP1 fw GCTACAGTGTCCCTCGAACC 
 rev CCGGTGCATGTGTCTCCTTA 
Human  
Connective tissue growth factor 
h-CTGF fw ACCGACTGGAAGACACGTTTG 
 rev CCAGGTCAGCTTCGCAAGG 
Human  
Connective tissue growth factor 
h-RPLPO fw CTCCAAGCAGATGCAGCAGA 
 rev ATAGCCTTGCGCATCATGGT 
Human  
Glyceraldehyde 3-phosphate 
dehydrogenase 
h-GAPDH fw TGC-CAT-GTA-GAC-CCC-TTG-AA 
 rev TGG-TTG-AGC-ACA-GGG-TAG-TT 
Human  
Myosin light chain 9 
h-Myl9 fw CGA-ATA-CCT-GGA-GGG-CAT-GAT 
 rev AAA-CCT-GAG-GCT-TCC-TCG-TC 
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3. Results 
3.1. Impaired Yes-Associated Protein (YAP) Nuclear Exclusion in Confluent LMNA Mutant Muscle Stem 
Cells (MuSCs) 
Wild-type (WT) MuSCs were plated either at low (10,000 cells/cm2) or high (40,000 cells/cm2) 
density and stained for YAP localization (Figure 1A,B). At low density, YAP was predominantly 
localized to the nucleus (Figure 1A,B). However, at high density conditions, WT cells showed 
predominantly cytoplasmic YAP, confirming previous reports for other cell types [26–28]. Similar 
YAP localization was observed in cells with the LMNAH222P mutation (Figure S1A,B) As expected, 
inhibition of CRM1-dependent nuclear export using Leptomycin B maintained preferential YAP 
nuclear distribution in confluent WT cells (Figure S2A). 
Interestingly, LMNA mutant cells plated at high density showed impaired density-dependent 
YAP subcellular localization and failed to exclude YAP from the nucleus (Figures 1A,B and S2B). 
 
Figure 1. Modulation of yes-associated protein (YAP) localization in wild-type (WT) and mutant 
muscle stem cells (MuSCs). (A) Confocal images of YAP (green) in WT and LMNAΔK32 mutant MuSCs 
cultured in low and high density conditions. Nuclei are stained with Hoechst (blue). Scale bar: 20 µm. 
(B) Quantification of YAP nucleo-cytoplasmic (N/C) ratio in WT, LMNAΔK32, LMNAL380S, LMNAR249W, 
and nesprin-1 KASK mutant MuSCs. Pooled values of WT (WT1 and WT2) are presented. Values are 
expressed as mean ± SEM, n = 200 cells for each cell line. * p < 0.05 vs WT; $ < 0.05 vs. corresponding 
sparse condition. (C) Micro-patterning modulation of YAP. Confocal images of YAP (green) in WT 
and LMNAΔK32 cells cultured on small ECM substrate that limits cell spreading. Nuclei are stained 
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with Hoechst (blue). Scale bar: 30 µm. (D) Quantification of YAP nucleo-cytoplasmic (N/C) ratio on 
small ECM substrates. Values are expressed as mean ± SEM, n ≥ 62 cells for each cell line. * p < 0.05 vs. 
WT. 
Lamin A/C’s are linked to the outer nuclear membrane protein nesprin-1 via SUN proteins in 
the lumen of the nuclear membrane. Nesprin-1 KASK mutation causes congenital myopathy and is also 
known to affect the nuclear shape [9,19]. Interestingly, nesprin-1 KASK cells displayed preferential 
nuclear YAP at high cell density (Figure 1B). Together, these finding revealed a striking correlation 
between the YAP mislocalization observed in vitro and the severity of the diseases. 
Apart from cell–cell contacts, mechanical environments characterized by cell morphology and 
actin contractility regulate YAP nuclear localization [28]. Small cell surface adhesion is a known 
determinant for YAP nuclear exclusion [28]. Accordingly, WT cells on round micro-patterned 
surfaces of 700 µm2 displayed low nuclear staining of YAP (Figure 1C,D). In contrast, YAP was 
preferentially nuclear in LMNAΔK32 cells cultured on small ECM substrates (Figure 1C,D). However, 
at low density, treatment with LatA induced YAP exclusion from the nucleus both in LMNAΔK32 
mutant and WT cells (Figure S2C), thus supporting a dominant regulation of YAP localization by 
actin polymerization. 
3.2. Phosphorylated Ser127-YAP Accumulates in the Nucleus of LMNA Mutated Muscle Stem  
Cells (MuSCs) 
YAP phosphorylation on Ser 127 residue by LATS1/2 allows interaction with 14–3–3 protein and 
thereby nuclear exclusion of YAP [29]. We thus asked whether persistent nuclear localization in 
LMNAΔK32 could be mediated by impaired LATS1/2 activity. 
We found that under high density conditions LMNAΔK32 cells accumulated pS127-YAP in the 
nucleus, in contrast to WT cells (Figure 2A,B). Interestingly, cell treatment with cytochalasin D a drug 
known to activate the Hippo pathway, increased the intensity of p127YAP staining (Figure S3), thus 
supporting the specificity of the pS127-YAP staining. 
 
Figure 2. pS127-YAP accumulates in the nucleus of LMNAΔK32 MuSCs. (A) Confocal images of pS127-YAP 
(green), in WT and LMNAΔK32 mutant MuSCs cultured at low and high density conditions. Nuclei are 
stained with Hoechst (blue). Scale bar: 20 µm. (B) Quantification of pS127-YAP nucleo-cytoplasmic 
(N/C) ratio. Values are expressed as mean ± SEM, n = 150 cells for each cell line.  
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* p < 0.005 compared with WT. (C) Representative Western-blot of YAP, pS127-YAP, and GAPDH in 
WT and LMNAΔK32 MuSCs plated at low and high cell density. (D) Quantification of pS127-YAP /YAP 
protein levels in low and high density conditions, expressed in arbitrary units (a.u.). GAPDH was 
used as a loading control. Pooled values of WT (WT1 and WT2) are presented. Values are mean ± 
SEM, n ≥ 4 per conditions. * p < 0.005 compared with WT. 
At low density, the amount of pS127-YAP did not differ between WT and LMNAΔK32, and the level 
of pS127-YAP and the pS127-YAP/YAP ratio significantly increase with cell density in both cell lines 
(Figure 1C,D). This is in line with data reporting a cell density-dependent activation of the Hippo 
pathway [26]. 
3.3. Src-Dependent Tyr Phosphorylation of YAP is Activated in LMNAΔK32 MuSCs 
Aside from pS127-YAP, tyrosine phosphorylation of YAP by Src-kinase family modulates the 
transcriptional activity of YAP and indirectly its localization [30]. In both WT and LMNAΔK32 cells, 
pY357-YAP was predominantly localized to the nucleus in low density conditions (Figure 3A,B). 
 
Figure 3. Y357 phosphorylation of YAP in WT and LMNA mutated MuSCs. (A) Confocal images of 
pY357-YAP (green) in WT and LMNAΔK32 mutant MuSCs cultured in low and high density conditions, 
at baseline and after treatment with Dasatinib. Nuclei are stained with Hoechst (blue). Scale bar: 20 
µm. (B) Quantification of pY357-YAP nucleo-cytoplasmic (N/C) ratio. Values are expressed as mean ± 
SEM, n = 150 cells for each cell line. (C) Representative Western-blot of YAP, pY357-YAP, and GAPDH 
in WT and LMNAΔK32 MuSCs plated at low and high cell density. (D) Quantification of pY357-YAP/YAP 
protein levels in low and high density conditions, expressed in arbitrary units (a.u.). GAPDH was 
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used as a loading control. Pooled values of WT (WT1 and WT2) are presented. Values are mean ± 
SEM, n ≥ 4 per conditions. * p < 0.005, ** p < 0.01, *** p < 0.001 compared with WT. (E) Representative 
Western-blot of YAP, pY357-YAP, and GAPDH in WT and LMNAΔK32 MuSCs treated with vehicle or 
Dasatinib. (F) Quantification of YAP, pY357-YAP, and pY357-YAP /YAP protein levels after treatment 
with Dasatinib. Values are expressed as percent change of values obtained without treatment. 
GAPDH was used as a loading control. Pooled values of WT (WT1 and WT2) are presented. Values 
are mean ± SEM, n ≥ 4 per conditions. * p < 0.005, ** p < 0.01, compared with WT. (G) Quantification 
of pY357-YAP nucleo-cytoplasmic (N/C) ratio after Dasatinib treatment expressed as a fraction of 
control value obtained in sparse or dense conditions before treatment. Values are expressed as mean 
± SEM, n ≥ 110 cells for each cell line. 
The nucleo-cytoplasmic ratio of pY357-YAP significantly decreased at high densities in WT but 
not in LMNAΔK32 mutant cells (Figure 3A,B). However, at the protein level, the pY357-YAP/YAP ratio 
did not differ between cell lines and decreased with cell density in both cell lines (Figure 3C,D). 
Dasatinib, an Abl and Src-family kinase inhibitor, significantly reduced the amount of pY357-YAP 
phosphorylation and the pY357-YAP/YAP ratio (Figure 3F,G) as well as the nucleo-cytoplasmic ratio 
of pY357-YAP (Figure 3A,H). 
3.4. Blockade of Nuclear Import Inhibits Nuclear Accumulation of YAP in Confluent LMNAΔK32 MuSCs 
It is clearly established that YAP localization depends on its dynamic shuttling between the 
cytoplasm and the nucleus, and is maintained at a steady state by a balance between nuclear export 
and import rates. To exclude the possibility of nonspecific permeabilization of the nuclear envelope 
due to the lamin mutation, and generally to determine the exact pathway of nuclear import of YAP, 
we used importazole, an importin β-specific inhibitor [24]. In low density cultures, importazole 
inhibited YAP nuclear localization in both WT and LMNAΔK32 cells, with no significant difference in 
YAP nucleo-cytoplasmic ratio between cell lines (Figure 4; each p < 0.001). In high density cultures, 
importazole significantly reduced nuclear localization of YAP in LMNAΔK32 cells (Figure 4A,B, each  
p < 0.001), but not in WT cells, thus attesting to a persistent nuclear import of YAP in high density 
LMNAΔK32 cell cultures. 
 
Figure 4. Importazole inhibits nuclear localization of YAP in WT and mutant MuSCs. (A) Confocal 
images of YAP (green) in WT and LMNAΔK32 mutant MuSCs cultured in low and high density 
conditions. Nuclei are stained with Hoechst (blue). Scale bar: 20 µm. (B) Quantification of YAP nucleo-
cytoplasmic (N/C) ratio after importazole treatment. Values are expressed as mean ± SEM, as a 
fraction of value obtained before importazole treatment, n ≥ 60 cell in each cell line. 
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3.5. Functional Consequences of YAP Nuclear Accumulation in High Density LMNA ΔK32 MuSCs 
To characterize the consequences of altered YAP translocation, we assessed expression of select 
YAP target genes and TEAD-dependent transcriptional activity using a luciferase reporter. Confluent 
LMNAΔK32 cells had an increased expression of YAP and YAP target genes CTGF and MYL9 (Figure 
5A). Moreover, LMNAΔK32 cells show increased TEAD-dependent luciferase reporter activity when 
compared to WT cells (Figure 5B), thus confirming elevated YAP transcriptional activity. Taken 
together, these data indicate that the LMNAΔK32 mutation affects YAP localization and density-
dependent inactivation of YAP. 
 
Figure 5. Transcriptional activity of YAP. (A) Histogram represents mRNA transcripts of YAP, CTGF, 
and Myl9 normalized to RPLP0 and expressed as fold-changes. Values are ± SEM, n = 3 separate 
experiments. * p < 0.05 compared with WT. (B) Quantification of YAP activity using the TBE-
Luciferase (LUC)/Renilla reporter. Values are ± SEM, n = 3 separate experiments. * p < 0.05 compared 
with WT cells. 
4. Discussion 
In this study, we showed that A-type lamin mutations which are responsible for congenital 
muscle disorders impacted the yes-associated protein (YAP) signaling pathway by increasing the 
nuclear import of YAP through the nuclear pore complexes. More importantly, YAP was 
transcriptionally active despite activation of the Hippo pathway, and thus may contribute to the 
impaired muscle differentiation in congenital muscle dystrophies. In addition, our data revealed a 
striking correlation between YAP deregulation, nuclear envelope defects, and disease severity, thus 
supporting a critical role of nuclear morphology in regulating YAP nuclear import. 
4.1. Canonical Regulation of YAP Nucleo-Cytoplasmic Localization Via the Hippo Pathway 
In skeletal muscle, YAP/transcriptional coactivator with PDZ-binding motif (TAZ) are powerful 
co-transcription factors which regulate muscle cell proliferation and differentiation [31,32] and play 
critical roles in controlling muscle growth [32,33]. The nuclear presence and the transcriptional 
activity of YAP/TAZ can be modulated by mechanical cues, such as substrate stiffness, cell spreading, 
and stretching (review in [34]) as well as by non-mechanical cues [26,35]. In previous work [10], we 
have shown that mutations in the LMNA gene associated to congenital muscle dystrophy cause a loss 
of environmental mechanosensing with elevated YAP signaling despite the soft environment, thus 
suggesting that A-type lamins modulate the mechanical regulation of YAP. Consistent with an 
abnormal mechanical regulation of YAP, we found that reducing cell spreading was ineffective to 
induce cytoplasmic relocalization of YAP in LMNA K32 mutant cells (Figure 1C,D). In addition, here 
we also showed that cell–cell contact failed to inhibit YAP nuclear localization and activity in LMNA 
mutant cells from LMNA-related congenital muscular dystrophy (L-CMD), contrary to what was 
observed in our wild-type (WT) (Figure 1A,B) and LMNAH222P (Figure S1) cells and in other non-
cancer cells [26–28]. Taken as a whole, these data showed that defective nucleo-cytoplasmic shuttling 
of YAP was a hallmark of the most severe muscle dystrophies related to nuclear envelope mutations. 
Moreover, abnormal YAP regulation in LMNA mutant cells from L-CMD involved both mechanical 
and non-mechanical regulations of YAP nucleo-cytoplasmic shuttling. While our study mainly 
focused on YAP, whether mutations in nuclear envelope proteins also affect the nucleo-cytoplasmic 
shuttling of TAZ remain to be precisely determined. 
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The mechanisms by which cell density modulates YAP activation and nucleo/cytoskeletal 
shuttling have been extensively studied during the last decade [11,36,37]. The Hippo signaling 
pathway critically regulates cell–cell contact-mediated YAP cytoplasmic translocation [38–40]. In cells 
grown at low density, YAP is primarily localized to the nucleus where it promotes target gene 
transcription and proliferation. When cells reach a critical density, YAP translocates to the cytoplasm 
[26–28], thus underlying the classical paradigm of the contact inhibition of proliferation [26]. The 
Hippo signaling pathway functions as a highly conserved canonical upstream regulator of YAP 
activity and localization [41]. At the core of the Hippo pathway, LAT1/2 mediates serine 
phosphorylation on several serine residues, including serine 127, thus mediating YAP nuclear export 
and subsequent cytoplasmic association with 14–3–3 proteins [40,42–44]. In confluent cultures, loss 
of Ser127 phosphorylation and LATS1/2 activity with persistent nuclear localization of YAP is a 
hallmark of cancer cells [30]. In contrast, the high density cultures of LMNA mutated cells exhibited 
high protein levels of pS127-YAP and persistent nuclear localization of pS127-YAP (Figure 2), thus 
indicating activation of the Hippo pathway signaling. This nuclear accumulation of YAP and pS127-
YAP in LMNAK32 cells suggests that YAP nuclear export is insufficient to counterbalance YAP 
nuclear entry. Accordingly, it is known that the presence of pS122-YAP is a prerequisite, but is not 
sufficient for nuclear exclusion of YAP [45,46]. Although the role of exportin1 in YAP nuclear export 
has been clearly identified [29,47,48], however, regulation of YAP nuclear export remains largely 
unknown. 
Regulation of YAP localization is also modulated by other kinases, including NLK [35] and Src-
family kinases [47,49]. Whereas YAP phosphorylation on Ser residues are well-known negative 
regulators of YAP stability, Src-mediated phosphorylation of tyrosine 357 has been correlated with 
nuclear localization and increased YAP transcriptional activity [18,47,49]. Higher pY357-YAP levels in 
LMNADK32 cells may thus contribute to the nuclear retention by promoting binding between YAP and 
TEAD transcription factors. Whether increased nuclear pY357-YAP at both low and high cell densities 
could explain the increased transcriptional activity of YAP observed in LMNA K32 cells (Figure 5) 
remains to be determined. 
4.2. Nuclear Import of YAP in LMNAΔK32 Mutant Cells 
YAP nuclear import is mediated by active translocation involving importins through nuclear 
pores [50]. To interfere with active nuclear import, we used importazole, a drug known to inhibit 
importin-dependent nuclear translocation [24] and YAP nuclear localization [18]. In low density 
conditions, blocking nuclear entry considerably reduced nuclear localization of YAP in both WT and 
LMNA mutant cells (Figure 4). Thus, in low density conditions, YAP nuclear entry was mediated by 
an importin-dependent nuclear import in both WT and LMNAΔK32 mutated MuSCs. Passive diffusion 
across the damaged nuclear envelope [51,52], if any, was not a main contributor of YAP nuclear 
import in LMNA K32 mutant MuSCs. Moreover, importazole inhibited YAP nuclear localization in 
high density LMNAΔK32 but not in WT cells. Therefore, in WT cells, at high cell density active nuclear 
import of YAP was inhibited and no further inhibition was observed after treatment with 
importazole. In contrast, active nuclear import of YAP persisted in LMNAΔK32 cells, a finding 
consistent with a dominant active nuclear import of YAP at cell confluence (Figure S4). MuSCs 
carrying a mutation in the gene encoding the nuclear envelope protein nesprin1, also failed to 
regulate YAP localization, thus suggesting a nuclear envelope-related dysfunction. 
Nuclear deformability is specific to LMNA and nesprin mutations rather than to muscular 
dystrophy and specifically affected the most severe forms of muscle disorders related to nuclear 
envelope defects [16,52]. Recent studies have reported that force-induced nuclear deformations 
increase YAP nuclear translocation through the nuclear pore complex [17,18]. It is thus conceivable 
that nuclear deformations per se drive nuclear translocation of YAP in LMNA and nesprin-1KASH 
mutant MuSCs (Figure S4), regardless of how nuclear deformation can be caused [53]. 
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4.3. Functional Consequence of YAP Deregulation in Myogenesis 
Nuclear localization of the transcriptional co-activator YAP and activation of the TEAD family 
transcription factors are required to promote proliferation but prevent differentiation of human stem 
cells [54,55]. In myogenic cell precursors cultured in vitro, high YAP expression and activity promotes 
proliferation of myogenic cell precursors whilst preventing their differentiation [31]. Therefore, one 
can speculate that persistent activation of YAP in LMNA mutant MuSCs has additive negative effects 
on skeletal muscle differentiation. Further studies are needed to precisely determine their 
contribution in the physiopathology of lamin-related muscle dystrophy. 
Supplementary Materials: The following are available online at www.mdpi.com/2073-4409/9/4/816/s1, Figure 
S1: (A) Confocal images of YAP (green) in confluent WT and LMNAH222P myogenic cells cultured in low and high 
density conditions. Nuclei are stained with Hoechst (blue). Scale bar: 50 µm. (B) Quantification of YAP nucleo-
cytoplasmic (N/C) ratio. Values are expressed as mean ± SEM, n ≥ 50 cells for each cell line, Figure S2: (A) 
Confocal images of YAP (green) and nuclei (blue) in confluent WT MuSCs treated with Leptomycin B (LB). Scale 
bar = 20 µm; (B) Confocal images of YAP (green) and nuclei (blue) in WT and LMNAΔK32 mutant MuSCs cultured 
in low and high density conditions. Nuclei are stained with Hoechst (blue). Scale bar: 20 µm. (C) Confocal images 
of YAP (green) and nuclei (blue) in confluent WT MuSCs treated with latrunculin A (LatA). Scale bar = 20 µm; 
(D) Quantification of YAP nucleo-cytoplasmic (N/C) ratio after Lat A treatment expressed as a fraction of control 
value obtained in sparse conditions. Values are expressed as mean ± SEM, n ≥ 60 cells for each cell line, *** p < 
0.001 versus value obtained before LatA treatment, Figure S3: Confocal images of p127-YAP (green) and nuclei 
(blue) in WT MuSCs treated with vehicle (DMSO) or Cytochalasin D (cyto D). Scale bar = 50 µm, Figure S4: 
Proposed model of the mechanisms by which lamins influence YAP subcellular distribution at high cell density. 
(A) In WT MuSCs plated at high cell density, the Hippo pathway is activated, and p127-YAP was excluded from 
the nucleus. YAP nuclear entry was lower than YAP nuclear export. (B) In L-CMD and nesprin-1DKASH mutations, 
YAP nuclear export is insufficient to counterbalance YAP nuclear entry despite activation of the Hippo pathway. 
This results in persistent nuclear localization of pS127-YAP nuclear import. Potential mechanisms imply increased 
nuclear deformability and/or dysfunctional LINC complex. 
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